Gilead Science公司在2025年取得了强有力的成果,其预防艾滋病毒药物YEZTUGO的第一年销售额为1亿5千万美元,并通过购置了8B美元扩大了肿瘤的覆盖范围。 Gilead Sciences achieved strong 2025 results with $150M in first-year sales for its HIV prevention drug YEZTUGO and expanded oncology reach through an $8B acquisition.

2025年,Gilead Science公司报告表现良好,其长效艾滋病毒预防药物YEZTUGO的第一年销售额高达1.5亿美元,显示出很高的效益和90%的付款率。 Gilead Sciences reported strong performance in 2025, highlighting $150 million in first-year sales for its long-acting HIV prevention drug YEZTUGO, which showed high effectiveness and 90% payer coverage. 该公司以80亿美元收购了Arcellx公司对Anito-cel的担保权利,Anito-cel是BAMA针对的细胞疗法,具有有利的安全特征,加强了肿瘤学组合,现在每年产生30亿美元。 The company's $8 billion acquisition of Arcellx secured rights to anito-cel, a BCMA-targeted cell therapy with a favorable safety profile, boosting its oncology portfolio, now generating $3 billion annually. Gilead强调艾滋病毒、肝病和肿瘤方面的持续增长,维持YEZTUGO8亿美元的销售目标,同时监测患者的持久性。 Gilead emphasized sustained growth across HIV, liver disease, and oncology, maintaining an $800 million sales target for YEZTUGO while monitoring patient persistence.